SMO and skin basal cell carcinoma: Even in BCC and MB, the decision to include a SMO inhibitor among the therapeutic options depends on the exact nature of the HH pathway activating mutation and also, potentially, the epigenetic mechanisms responsible for maintaining pathway activity.